This subtype of tumors was noted to have hypermethylation in the MLH1 promoter region (leading to MLH1 silencing), and targetable hotspot mutations in PIK3CA, ERBB3, ERBB2, and EGFR. Of note, the BRAFV600E mutation commonly seen in MSI colorectal cancer was absent. Here, MLH1 is linked to colorectal cancer.